<DOC>
	<DOC>NCT00255268</DOC>
	<brief_summary>To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated. QoL evaluation is also included.</brief_summary>
	<brief_title>CMAB vs IMAB in Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<criteria>Histological diagnosis of D2 of Adenocarcinoma, Naivety to treatment Valuable bone metastasis Hematological, liver or renal toxicity Grade IV Severe and active infections</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>